EXCLUSIVE: AI Has A Blind Spot, Here Are 3 Overlooked Stocks
Jensen’s Allen Bond says investors may be overlooking Veeva, Verisk and Broadridge as AI reshapes software and business services.
Stocks · News reference
Veeva Systems Announces AI Study Builder Agent To Configure Clinical Studies From Protocols, Delivered As Claude Cowork Plugin
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
Veeva Systems announced the launch of Falcon Router, an AI-powered agentic solution designed to automate the intake and routing of safety, quality, and medical cases for biopharma companies. The solution, available for early adoption in January 2027, will integrate with Veeva's Safety, QMS, and MedInquiry platforms to reduce manual workloads and improve compliance workflows. The announcement reinforces Veeva's AI strategy focused on workflow automation within its Vault ecosystem.
Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today
A $1,000 investment in Veeva Systems (VEEV) made in September 2016 would be worth $6,261.92 as of September 22, 2026, representing a 526.19% gain. This significantly outperformed the S&P 500's 258.96% gain over the same period. Veeva continues to benefit from strong demand for life sciences cloud platforms, with fiscal 2026 revenues reaching $3.19 billion (up 16% YoY) and adjusted EPS of $8.10 (up 22.7% YoY).